Thymalin — safety
Adverse events as reported, contraindications, warnings, and an explicit statement of what the safety evidence does not establish.
§4Safety
§4.1Adverse events reported in controlled trials
Table 4. Adverse events for Thymalin as reported in the trial safety tables the Institute holds. Percentages are of randomised participants in the stated trial and arm.
| Event | Active, % | Comparator, % | Difference, pp | Source |
|---|---|---|---|---|
| Injection-site reaction | — | — | — | Reported |
| Allergic reaction | — | — | — | A bovine-derived extract carries an inherent immunogenicity and allergy risk that a synthetic peptide does not |
| Transmissible agent risk | — | — | — | Any bovine-tissue-derived product carries a theoretical transmissible spongiform encephalopathy risk requiring documented sourcing controls |
| A difference column is computed by the Institute from the two reported percentages and is not itself a published figure. Confidence intervals for adverse-event differences are not reported in the contributing trials and are not constructed here. | ||||
§4.2Contraindications
- As stated in the Russian labelling
- Known hypersensitivity to bovine protein
§4.3Warnings and precautions
- Bovine-derived; sourcing and viral- and prion-safety documentation are essential and are not part of any research-supply certificate the Institute has assessed
- Composition is undefined, so batch consistency cannot be verified analytically
- Approval in one jurisdiction is not assessable efficacy evidence
§4.4What this section does not establish
Related assessments: tolerability of incretin receptor agonists · acute pancreatitis · the rodent thyroid C-cell signal.[1,2]
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- United States Pharmacopeial Convention. General Chapter ⟨85⟩ Bacterial Endotoxins Test. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
- United States Pharmacopeial Convention. General Chapter ⟨71⟩ Sterility Tests. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.